For more information contact the Lawrence Wilson Art Gallery:
Paul Anderson has over 14 years experience in the medical device and cellular therapeutic fields with expertise in bridging the gap between research and clinical practice in the development of emerging medical technologies. This encompasses applying the regulatory framework to product and the accompanying ‘grey area’ interpretation, rebating pathways, marketing, sales, developing orthopaedic relationships, strategic and financial planning. Paul has a strong track record with his previous board position with Verigen Australia Pty Ltd, a human cell therapies company.
Image: Paul Anderson
From as early as the 1600s, concepts and ideas defining regenerative medicine have evolved to provide great hope in curing diseases and healing tissues. Regenerative approaches involving cell scaffolds and growth factors are finding their way into today’s treatment options and are providing solutions to difficult clinical problems - which if unchecked - ultimately affect activities of daily living and put an enormous burden on society.
An ageing population is resulting in an explosion of concerns involving musculoskeletal issues that provide great impetus to finding more sophisticated and cost effect ways of treating patients. Regenerative medicine and biological therapies are already finding their way into the clinic and common usage. These range from simple scaffold approaches using human tissue to synthetics, hybrids and to more complex cellular therapies and tissue regenerating opportunities of 3D printing.
It is an exciting era of translational work, with greater understanding of the complexity of the problems, enabling innovative interventions that address the underlying pathology and which are founded on a strong evidence base.